Medical Use
ZOLGENSMA is a gene therapy utilizing an adeno-associated virus vector, designed for treating pediatric patients under 2 years old who have spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene.
Limitations of Use:
- The safety and efficacy of administering ZOLGENSMA more than once have not been studied.
- ZOLGENSMA has not been evaluated in patients with advanced stages of SMA, such as those with complete limb paralysis or permanent dependence on a ventilator.
Warning & Precautions
ZOLGENSMA may elevate liver enzyme levels and lead to severe liver injury or acute liver failure, potentially resulting in death. Patients will be given an oral corticosteroid before and after the infusion of ZOLGENSMA and will have regular blood tests to monitor liver function.
If the patient’s skin or the whites of their eyes turn yellow, if they miss a dose of corticosteroid or vomit it up, or if they become less alert, contact their doctor immediately.
Documentation Availability
Documents required to import ZOLGENSMA to India?
ZOLGENSMA can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing ZOLGENSMA from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the most important information I should know about ZOLGENSMA®?
Infections occurring before or after a ZOLGENSMA infusion can result in more severe complications. Caregivers and those in close contact with the patient should adhere to infection prevention measures. If the patient shows any signs of infection, such as coughing, wheezing, sneezing, a runny nose, sore throat, or fever, contact their doctor immediately.
Following a ZOLGENSMA infusion, there may be a decrease in platelet counts. Immediate medical attention is necessary if the patient experiences unexpected bleeding or bruising.
Thrombotic microangiopathy (TMA) has been reported, typically within the first two weeks after a ZOLGENSMA infusion. Seek urgent medical care if the patient shows signs or symptoms of TMA, such as unexpected bruising or bleeding, seizures, or reduced urine output.
There is also a theoretical risk of tumor development associated with gene therapies like ZOLGENSMA.
Who manufactures ZOLGENSMA®?
ZOLGENSMA® is manufactured by Novartis Gene Therapies
What are the possible or likely side effects of ZOLGENSMA®?
The most common side effects that occurred in patients treated with ZOLGENSMA were elevated liver enzymes and vomiting.
Do I need to take precautions with the patient's bodily waste?
For a short period, traces of ZOLGENSMA might be present in the patient’s stool. It’s important to practice good hand hygiene when handling the patient’s body waste for one month following the infusion. Disposable diapers should be securely sealed in trash bags and disposed of with regular household waste.
Is it safe to buy ZOLGENSMA ®online in India?
ZOLGENSMA ®can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
